Close-up of microscope and sample with blue glove.

Funding excellent research

Aiming for a life without EB

EB Resnet supports and coordinates research funding on behalf of its member patient organisations and partners. We currently offer three funding schemes: Research grants through scheduled Calls for proposals, Ad-hoc grants our flexible funding scheme, and Co-funding for industry-partnering projects.

EB Resnet welcomes proposals for innovative research and clinical development of treatments or diagnostics. All proposals are evaluated for scientific excellence, feasibility and value for money, and whether they address the priority needs of people with EB. We undertake peer review to ensure that only the best research is funded.

Our funding schemes. How do your ideas fit in?

Research grants	Ad-hoc grants	Industry co-funding
You are engaged in fundamental to preclinical research or clinical trials in EB Your project idea falls within the scope of a Current research Call (All priorities Call or Special Call in spring and/or autumn) You are working in academia, or in a clinic (cooperation with industry welcome) Your project objectives can be achieved in 12 to 36 months and financed with up to EUR 90,000.00 p.a.	You are engaged in fundamental research to preclinical or clinical trials in EB You are in need of quick funding to respond to an arising opportunity in fundamental to preclinical research or proof of concept project Your project idea falls within the scope of a Special Ad-hoc Call You are working in academia, in a clinic or in industry Your project can be undertaken within one year (renewable if results are promising) and financed with up to EUR 100,000.00 p.a.	You are engaged in translational research and undertaking clinical trials in EB Your project is in late preclinical to clinical stage You are working in the industry and/or in cooperation with academia The project needs additional funding of up to EUR 250,000.00 to be realised

Research grants

Ad-hoc grants

Industry co-funding

AP Call 2022

closed since 06 September 2022

Special Ad-hoc Call 2022 - Repurposing

closed since 06 September 2022

Open

You are engaged in fundamental to preclinical research or clinical trials in EB
Your project idea falls within the scope of a Current research Call (All priorities Call or Special Call in spring and/or autumn)
You are working in academia, or in a clinic (cooperation with industry welcome)
Your project objectives can be achieved in 12 to 36 months and financed with up to EUR 90,000.00 p.a.

You are engaged in fundamental research to preclinical or clinical trials in EB
You are in need of quick funding to respond to an arising opportunity in fundamental to preclinical research or proof of concept project
Your project idea falls within the scope of a Special Ad-hoc Call
You are working in academia, in a clinic or in industry
Your project can be undertaken within one year (renewable if results are promising) and financed with up to EUR 100,000.00 p.a.

You are engaged in translational research and undertaking clinical trials in EB
Your project is in late preclinical to clinical stage
You are working in the industry and/or in cooperation with academia
The project needs additional funding of up to EUR 250,000.00 to be realised

Closed Calls 2022

This year's All Priorities Call closed on 06 September 2022. Full details including deadlines and scope are displayed under Closed Call 'AP Call 2022'.

In addition, a Special Ad-hoc Call 2022 focussing on Proof-of-Concept Proposals on Drug Repurposing for EB closed on 06 September 2022 too. Full details including deadlines and scope are displayed under Closed Call 'Special Ad-hoc Call 2022'.

The results of the All Priorities Call 2021 can be found in the overview table for 2021.

Closed Call

All Priorities Call 2022

Closed Call

Special Ad-Hoc Call 2022